We are live on ! Find out more
TTPH

Tetraphase Pharmaceuticals, Inc.
TTPH

Delisted

TTPH was delisted on the 28th of July, 2020.

105 hedge funds and large institutions have $212M invested in Tetraphase Pharmaceuticals, Inc. in 2015 Q3 according to their latest regulatory filings, with 19 funds opening new positions, 46 increasing their positions, 29 reducing their positions, and 52 closing their positions.

New
Increased
Maintained
Reduced
Closed

59% more repeat investments, than reductions

Existing positions increased: 46 | Existing positions reduced: 29

21% less call options, than puts

Call options by funds: $4.75M | Put options by funds: $6.01M

24% less funds holding

Funds holding: 139105 (-34)

50% less funds holding in top 10

Funds holding in top 10: 21 (-1)

63% less first-time investments, than exits

New positions opened: 19 | Existing positions closed: 52

84% less capital invested

Capital invested by funds: $1.3B → $212M (-$1.09B)

Holders
105
Holders Change
-34
Holders Change %
-24.46%
% of All Funds
2.93%
Holding in Top 10
1
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-50%
% of All Funds
0.03%
New
19
Increased
46
Reduced
29
Closed
52
Calls
$4.75M
Puts
$6.01M
Net Calls
-$1.26M
Net Calls Change
-$883K
Name Holding Trade Value Shares
Change
Change in
Stake
HT
51
HAP Trading
New York
$411K -$732K -998 -27%
AllianceBernstein
52
AllianceBernstein
Tennessee
$396K -$36.9M -50,303 -95%
Citadel Advisors
53
Citadel Advisors
Florida
$379K -$12.2M -16,619 -87%
GF
54
Gabelli Funds
New York
$373K -$3.52M -4,800 -66%
CS
55
Credit Suisse
Switzerland
$336K -$523K -713 -24%
UBS Group
56
UBS Group
Switzerland
$302K +$68.3K +93 +5%
WJA
57
Williams Jones & Associates
New York
$283K +$1.39M +1,894 New
Swiss National Bank
58
Swiss National Bank
Switzerland
$278K +$198K +270 +17%
D.E. Shaw & Co
59
D.E. Shaw & Co
New York
$276K +$1.07M +1,460 +376%
Morgan Stanley
60
Morgan Stanley
New York
$268K -$44.8K -61 -3%
RhumbLine Advisers
61
RhumbLine Advisers
Massachusetts
$253K +$37.4K +51 +3%
New York State Common Retirement Fund
62
New York State Common Retirement Fund
New York
$246K -$312K -425 -20%
ProShare Advisors
63
ProShare Advisors
Maryland
$233K -$80.7K -110 -7%
LCM
64
Laurion Capital Management
New York
$229K +$1.13M +1,535 New
SG Americas Securities
65
SG Americas Securities
New York
$193K +$949K +1,293 New
MLICM
66
Metropolitan Life Insurance Company (MetLife)
New York
$189K
BA
67
BlackRock Advisors
Delaware
$176K -$15.6M -21,318 -95%
NFA
68
Nationwide Fund Advisors
Ohio
$175K -$663K -904 -44%
AIG
69
American International Group
New York
$168K +$1.47K +2 +0.2%
BAMS
70
Bellevue Asset Management (Switzerland)
Switzerland
$164K +$367K +500 +83%
Wells Fargo
71
Wells Fargo
California
$158K -$7.64M -10,412 -91%
Goldman Sachs
72
Goldman Sachs
New York
$155K +$405K +552 +114%
VKH
73
Virtu KCG Holdings
New York
$154K +$760K +1,035 New
State Board of Administration of Florida Retirement System
74
State Board of Administration of Florida Retirement System
Florida
$147K +$5.87K +8 +0.8%
Barclays
75
Barclays
United Kingdom
$139K +$315K +429 +76%

TTPH Hedge Fund Activity: Q3 2015 in Review

105 of the 3,582 institutional investors tracked by Wall St. Rank reported a position in Tetraphase Pharmaceuticals, Inc. (TTPH) for Q3 2015, worth a combined $212M — down 84% from $1.3B a quarter earlier.

Sellers outnumbered buyers: 52 funds closed out of TTPH and 19 opened new positions — a net loss of 33 holders — while 29 trimmed existing stakes and 46 added.

The largest buyer was State Street, adding an estimated $84.5M. The largest seller was Jennison Associates, exiting entirely with an estimated $53.3M sold.

  • 105 institutional investors held Tetraphase Pharmaceuticals, Inc. (TTPH) as of Q3 2015, down from 139 in Q2 2015.
  • Funds reported $212M of Tetraphase Pharmaceuticals, Inc. stock for Q3 2015, down 84% quarter-over-quarter.
  • 19 funds opened new Tetraphase Pharmaceuticals, Inc. positions in Q3 2015 and 52 closed out, a net change of -33 holders.
  • The largest Tetraphase Pharmaceuticals, Inc. buyer in Q3 2015 was State Street, an estimated $84.5M added.
  • The largest Tetraphase Pharmaceuticals, Inc. seller in Q3 2015 was Jennison Associates, an estimated $53.3M sold.

Based on aggregated 13F filings for Q3 2015.